0.28  0 (0%)		04-22 15:33
Open: 0.28 High: 0.28 Volume: 2,239		Pre. Close: 0.28 Low: 0.28 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.41	1-year :	0.47
Resists	First :	0.35	Second :	0.4
Pivot price	0.3
Supports	First :	0.26	Second :	0.22
MAs	MA(5) :	0.29	MA(20) :	0.31
	MA(100) :	0.34	MA(250) :	0.37
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	36.3	D(3) :	29.9
RSI	RSI(14): 42.5
52-week	High :	1.11	Low :	0.26

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PBLA ] has closed above bottom band by 14.2%. Bollinger Bands are 22.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.32 - 0.32	0.32 - 0.32
Low:	0.28 - 0.28	0.28 - 0.28
Close:	0.32 - 0.32	0.32 - 0.32

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Thu, 14 Nov 2024
Panbela Therapeutics Inc (PBLA) Quarterly 10-Q Report - qz.com

Thu, 14 Nov 2024
Panbela Provides Business Update and Reports Q3 2024 Financial Results - GlobeNewswire

Sat, 11 May 2024
Panbela Therapeutics (PBLA) Stock Forecast and Price Target 2025 - MarketBeat

Mon, 29 Jan 2024
Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today? - InvestorPlace

Thu, 21 Dec 2023
Panbela Therapeutics Announces Exercise of Warrants and - GlobeNewswire

Fri, 03 Nov 2023
Why Panbela Therapeutics (PBLA) Stock Is Nosediving - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	5 (M)
Shares Float	5 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	107 (K)
Shares Short P.Month	46 (K)

EPS	121.66
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-2.19
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-128.4 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-20 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-0.13
Price to Sales	0
Price to Cash Flow	-0.07

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.